Recent research suggests that metformin, a routinely used diabetic medicine, may provide cardiovascular (CV) benefits regardless of diabetes present. This calls into question the conventional wisdom that diabetes and cardiovascular disease (CVD) require distinct treatments. Large randomized controlled trials have demonstrated CV advantages for two groups of diabetes and cardiovascular medicines, SGLT2 inhibitors and GLP-1 receptor agonists. Researchers have created a new trial called VA-IMPACT to examine whether metformin belongs in the same group. This is the first placebo-controlled CV outcomes trial including metformin. The study’s goal is to see if metformin is linked to fewer significant adverse CV events in those with prediabetes and atherosclerotic CVD. Metformin, a low-cost generic medicine, was formerly recommended as a first-line treatment.

To know more: About the original article click here.